201
Participants
Start Date
November 30, 2012
Primary Completion Date
March 8, 2021
Study Completion Date
March 8, 2021
Tenofovir
300 mg daily for 192 weeks (4 years)
Peginterferon-alfa 2a and tenofovir
A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).
NIH Clinical Center, Bethesda
Virginia Commonwealth University, Richmond
University of North Carolina, Chapel Hill
Duke University Medical Center, Durham
University of Michigan Health System, Ann Arbor
University of Minnesota, Plymouth
Mayo Clinic, Rochester
Saint Louis University, St Louis
Washington University, St Louis
Baylor University Medical Center, Dallas
University of Texas Southwestern, Dallas
Cedars Sinai Medical Center, Los Angeles
University of California Los Angeles, Los Angeles
California Pacific Medical Center, San Francisco
University of California San Francisco, San Francisco
Queen's Medical Center, Honolulu
Virginia Mason Medical Center, Seattle
University of Washington Medical Center, Seattle
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
University of Toronto-Toronto Western Hospital, Toronto
University of Pittsburgh
OTHER
National Center for Research Resources (NCRR)
NIH
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH